Efficacy of losartan and carvedilol on central hemodynamics in hypertensives

A prospective, randomized, open, blinded end point, multicenter study

Eung Ju Kim, Woohyuk Song, Jae Ung Lee, Mi Seung Shin, Sahng Lee, Byeong Ok Kim, Kyeong Sun Hong, Seong Woo Han, Chang Gyu Park, Hong Seog Seo

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Renin-angiotensin system (RAS) blockers have shown clinical outcomes superior to those of the beta (β)-blocker atenolol, despite similar reductions in the peripheral blood pressure (BP), perhaps because of different impacts on central hemodynamics. However, few comparative studies of RAS blockers and newer vasodilating β-blockers have been performed. We compared the central hemodynamic effects of losartan and carvedilol in a prospective, randomized, open, blinded end point study. Of the 201 hypertensive patients enrolled, 182 (49.6±9.9 years, losartan group=88 and carvedilol group=94) were analyzed. Carotid-femoral pulse wave velocity (cfPWV), aortic augmentation index (AIx), AIx corrected for a heart rate (HR) of 75 beats per minute (AIx@HR75) and central BP were measured noninvasively at baseline and after a 24-week treatment regimen with losartan or carvedilol. After 24 weeks, there were no between-group differences in the brachial BP, cfPWV, AIx@HR75 or central BP changes, except for a more favorable AIx effect with losartan. The changes in all measured metabolic and inflammatory parameters were also not significantly different between the two groups, except for uric acid. Losartan and carvedilol showed generally comparable effects on central hemodynamic indices, metabolic profile, inflammatory parameters and peripheral arterial pressure with a 24-week treatment.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalHypertension Research
Volume37
Issue number1
DOIs
Publication statusPublished - 2014 Jan 13

Fingerprint

Losartan
Multicenter Studies
Hemodynamics
Blood Pressure
Pulse Wave Analysis
Renin-Angiotensin System
Thigh
Atenolol
Metabolome
Uric Acid
Arterial Pressure
Arm
Heart Rate
carvedilol
Therapeutics

Keywords

  • blood pressure
  • carvedilol
  • central hemodynamics
  • hypertension
  • losartan

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy of losartan and carvedilol on central hemodynamics in hypertensives : A prospective, randomized, open, blinded end point, multicenter study. / Kim, Eung Ju; Song, Woohyuk; Lee, Jae Ung; Shin, Mi Seung; Lee, Sahng; Kim, Byeong Ok; Hong, Kyeong Sun; Han, Seong Woo; Park, Chang Gyu; Seo, Hong Seog.

In: Hypertension Research, Vol. 37, No. 1, 13.01.2014, p. 50-56.

Research output: Contribution to journalArticle

@article{68c844c92ee141b68a39ee45bdf778bb,
title = "Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: A prospective, randomized, open, blinded end point, multicenter study",
abstract = "Renin-angiotensin system (RAS) blockers have shown clinical outcomes superior to those of the beta (β)-blocker atenolol, despite similar reductions in the peripheral blood pressure (BP), perhaps because of different impacts on central hemodynamics. However, few comparative studies of RAS blockers and newer vasodilating β-blockers have been performed. We compared the central hemodynamic effects of losartan and carvedilol in a prospective, randomized, open, blinded end point study. Of the 201 hypertensive patients enrolled, 182 (49.6±9.9 years, losartan group=88 and carvedilol group=94) were analyzed. Carotid-femoral pulse wave velocity (cfPWV), aortic augmentation index (AIx), AIx corrected for a heart rate (HR) of 75 beats per minute (AIx@HR75) and central BP were measured noninvasively at baseline and after a 24-week treatment regimen with losartan or carvedilol. After 24 weeks, there were no between-group differences in the brachial BP, cfPWV, AIx@HR75 or central BP changes, except for a more favorable AIx effect with losartan. The changes in all measured metabolic and inflammatory parameters were also not significantly different between the two groups, except for uric acid. Losartan and carvedilol showed generally comparable effects on central hemodynamic indices, metabolic profile, inflammatory parameters and peripheral arterial pressure with a 24-week treatment.",
keywords = "blood pressure, carvedilol, central hemodynamics, hypertension, losartan",
author = "Kim, {Eung Ju} and Woohyuk Song and Lee, {Jae Ung} and Shin, {Mi Seung} and Sahng Lee and Kim, {Byeong Ok} and Hong, {Kyeong Sun} and Han, {Seong Woo} and Park, {Chang Gyu} and Seo, {Hong Seog}",
year = "2014",
month = "1",
day = "13",
doi = "10.1038/hr.2013.112",
language = "English",
volume = "37",
pages = "50--56",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Efficacy of losartan and carvedilol on central hemodynamics in hypertensives

T2 - A prospective, randomized, open, blinded end point, multicenter study

AU - Kim, Eung Ju

AU - Song, Woohyuk

AU - Lee, Jae Ung

AU - Shin, Mi Seung

AU - Lee, Sahng

AU - Kim, Byeong Ok

AU - Hong, Kyeong Sun

AU - Han, Seong Woo

AU - Park, Chang Gyu

AU - Seo, Hong Seog

PY - 2014/1/13

Y1 - 2014/1/13

N2 - Renin-angiotensin system (RAS) blockers have shown clinical outcomes superior to those of the beta (β)-blocker atenolol, despite similar reductions in the peripheral blood pressure (BP), perhaps because of different impacts on central hemodynamics. However, few comparative studies of RAS blockers and newer vasodilating β-blockers have been performed. We compared the central hemodynamic effects of losartan and carvedilol in a prospective, randomized, open, blinded end point study. Of the 201 hypertensive patients enrolled, 182 (49.6±9.9 years, losartan group=88 and carvedilol group=94) were analyzed. Carotid-femoral pulse wave velocity (cfPWV), aortic augmentation index (AIx), AIx corrected for a heart rate (HR) of 75 beats per minute (AIx@HR75) and central BP were measured noninvasively at baseline and after a 24-week treatment regimen with losartan or carvedilol. After 24 weeks, there were no between-group differences in the brachial BP, cfPWV, AIx@HR75 or central BP changes, except for a more favorable AIx effect with losartan. The changes in all measured metabolic and inflammatory parameters were also not significantly different between the two groups, except for uric acid. Losartan and carvedilol showed generally comparable effects on central hemodynamic indices, metabolic profile, inflammatory parameters and peripheral arterial pressure with a 24-week treatment.

AB - Renin-angiotensin system (RAS) blockers have shown clinical outcomes superior to those of the beta (β)-blocker atenolol, despite similar reductions in the peripheral blood pressure (BP), perhaps because of different impacts on central hemodynamics. However, few comparative studies of RAS blockers and newer vasodilating β-blockers have been performed. We compared the central hemodynamic effects of losartan and carvedilol in a prospective, randomized, open, blinded end point study. Of the 201 hypertensive patients enrolled, 182 (49.6±9.9 years, losartan group=88 and carvedilol group=94) were analyzed. Carotid-femoral pulse wave velocity (cfPWV), aortic augmentation index (AIx), AIx corrected for a heart rate (HR) of 75 beats per minute (AIx@HR75) and central BP were measured noninvasively at baseline and after a 24-week treatment regimen with losartan or carvedilol. After 24 weeks, there were no between-group differences in the brachial BP, cfPWV, AIx@HR75 or central BP changes, except for a more favorable AIx effect with losartan. The changes in all measured metabolic and inflammatory parameters were also not significantly different between the two groups, except for uric acid. Losartan and carvedilol showed generally comparable effects on central hemodynamic indices, metabolic profile, inflammatory parameters and peripheral arterial pressure with a 24-week treatment.

KW - blood pressure

KW - carvedilol

KW - central hemodynamics

KW - hypertension

KW - losartan

UR - http://www.scopus.com/inward/record.url?scp=84891750249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891750249&partnerID=8YFLogxK

U2 - 10.1038/hr.2013.112

DO - 10.1038/hr.2013.112

M3 - Article

VL - 37

SP - 50

EP - 56

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 1

ER -